Herpes Labialis News and Research

RSS
Herpes labialis or "orolabial herpes" is an infection of the lip by herpes simplex virus. An outbreak typically causes small blisters or sores on or around the mouth commonly known as cold sores or fever blisters.
BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

FDA notification confirms acyclovir Lauriad for oro-facial herpes labialis

FDA notification confirms acyclovir Lauriad for oro-facial herpes labialis

Medivir appoints Daewoong as South Korean distributor for Xerclear

Medivir appoints Daewoong as South Korean distributor for Xerclear

NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation receives U.S. patent for nanoemulsion technology

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

NanoBio to develop intranasal vaccine for HBV

NanoBio to develop intranasal vaccine for HBV

Medivir, Meda announce agreement to commercialize Medivir’s cold sore product, Xerese

Medivir, Meda announce agreement to commercialize Medivir’s cold sore product, Xerese

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

Swedish agency approves Medivir's Xerclear for treatment of cold sores

Swedish agency approves Medivir's Xerclear for treatment of cold sores

GSK and NanoBio sign license agreement for nanoemulsion technology

GSK and NanoBio sign license agreement for nanoemulsion technology

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

Positive results from BioAlliance Pharma's acyclovir Lauriad phase III trial

Positive results from BioAlliance Pharma's acyclovir Lauriad phase III trial

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

European authorities approve Medivir’s marketing authorisation application in 14 European countries

European authorities approve Medivir’s marketing authorisation application in 14 European countries

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Clinical trial data of Lipsovir presented at ICAAC

Clinical trial data of Lipsovir presented at ICAAC

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

US FDA approves Lipsovir for cold sores

US FDA approves Lipsovir for cold sores